List view / Grid view
In this exclusive interview, Torsten Madsen, CEO of Hoba Therapeutics, highlights the current clinical development landscape, challenges, and opportunities for pain management medicines.
The prescription drug pregabalin is now being treated as a class C drug...
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
19 July 2012 | By Pfizer
“The Court’s decision recognizes the infringement & validity of our LYRICA® patents..."
18 May 2012 | By Pfizer
Results of studies on Lyrica® announced...
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
5 July 2011 | By Pfizer
Pfizer Japan announced the top-line results for Lyrica (pregabalin) Study A0081208...
21 June 2011 | By Pfizer
Pfizer Inc. announced that top-line results for Lyrica Study A0081107, demonstrated that the study met its primary endpoint...
